The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel
- PMID: 9580754
- DOI: 10.1016/s0022-3476(98)70344-0
The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel
Abstract
The diagnostic criteria proposed here are not likely to cover every possible clinical scenario, and there will be clinical dilemmas. For the vast majority of patients with CF, the diagnosis will be suggested by the presence of one or more characteristic clinical features, a history of CF in a sibling, or a positive newborn screening test result and will then be confirmed by laboratory evidence of CFTR dysfunction (Table V). Abnormal CFTR function will usually be documented by two elevated sweat chloride concentrations obtained on separate days or identification of two CF mutations. For patients in whom sweat chloride concentrations are normal or borderline and in whom two CF mutations are not identified, an abnormal nasal PD measurement recorded on 2 separate days can be used as evidence of CFTR dysfunction. Clinical judgment will continue to be essential in patients who have typical or "atypical" clinical features but who lack conclusive evidence of CFTR dysfunction. Such patients will require close clinical follow-up along with laboratory reevaluation as appropriate.
Comment in
-
Making the diagnosis of cystic fibrosis.J Pediatr. 1998 Apr;132(4):563-5. doi: 10.1016/s0022-3476(98)70337-3. J Pediatr. 1998. PMID: 9580747 No abstract available.
Similar articles
-
Laboratory tests for the diagnosis of cystic fibrosis.Am J Clin Pathol. 2002 Jun;117 Suppl:S109-15. doi: 10.1309/XTM9-E4BU-C1Y5-JN10. Am J Clin Pathol. 2002. PMID: 14569807 Review.
-
Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.Thorax. 2010 Jun;65(6):539-44. doi: 10.1136/thx.2009.123422. Thorax. 2010. PMID: 20522854
-
Nasal potential difference measurements in patients with atypical cystic fibrosis.Eur Respir J. 2001 Jun;17(6):1208-15. doi: 10.1183/09031936.01.00092501. Eur Respir J. 2001. PMID: 11491166
-
Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism.J Cyst Fibros. 2020 Jul;19(4):627-631. doi: 10.1016/j.jcf.2019.07.001. Epub 2019 Jul 19. J Cyst Fibros. 2020. PMID: 31331863
-
The diagnosis of cystic fibrosis.Presse Med. 2017 Jun;46(6 Pt 2):e97-e108. doi: 10.1016/j.lpm.2017.04.010. Epub 2017 May 31. Presse Med. 2017. PMID: 28576637 Review.
Cited by
-
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.Cochrane Database Syst Rev. 2024 May 3;5(5):CD009530. doi: 10.1002/14651858.CD009530.pub5. Cochrane Database Syst Rev. 2024. PMID: 38700027 Review.
-
Galectin-3 levels in children with cystic fibrosis.Eur J Pediatr. 2024 May;183(5):2333-2342. doi: 10.1007/s00431-024-05479-6. Epub 2024 Mar 2. Eur J Pediatr. 2024. PMID: 38430280
-
Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF).PLoS One. 2024 Feb 20;19(2):e0292270. doi: 10.1371/journal.pone.0292270. eCollection 2024. PLoS One. 2024. PMID: 38377145 Free PMC article.
-
Nebuliser systems for drug delivery in cystic fibrosis.Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3. Cochrane Database Syst Rev. 2023. PMID: 37942828 Free PMC article. Review.
-
Prevalence of Anemia and its Relation with Shwachman Score in Children with Cystic Fibrosis.Tanaffos. 2023 Jan;22(1):160-166. Tanaffos. 2023. PMID: 37920324 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
